ALX Oncology Reports Q1 2022 Financial Results, Provides Clinical Updates for Evorpacept

ALX ONCOLOGY HOLDINGS INC

2023-Q1 EPS reported -$0.60

First patient dosed in Phase 2/3 ASPEN-06 study evaluating evorpacept in HER2-positive gastric/GEJ cancer.
FDA granted Orphan Drug Designation to evorpacept for treatment of gastric/GEJ cancer.
Cash, cash equivalents and investments totaled $341.7 million as of March 31, 2022, expected to fund operations through mid-2024.
GAAP net loss for Q1 2022 was $24.5 million ($0.60 per share), compared to $14.2 million ($0.35 per share) in Q1 2021.
Appointed Itziar Canamasas, Ph.D. to its Board of Directors in April 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.